Dr. Felix Kratz
Tumor Biology Center, German

Email: kratz@tumorbio.uni-freiburg.de

Qualifications
1991  Postdoctoral researcher, Bioinorganic Institute, University of Florence
1988  Ph.D., Inorganic Department of Chemistry, University of Heidelberg

Publications (Selected)

1. M. Calderón, R. Haag, F. Kratz (2011): Säurelabile Nanotransporter als neuartige Drug-Delivery-Systeme zur Behandlung von Krebserkrankungen,Journal Onkologie 3, 152-155.
2. D. Ren, F. Kratz, S. Wang (2011): Protein nanocapsules containing doxorubicin as a pH-responsive delivery system,Small, 7,1051-60.
3. Anticancer macromolecular prodrugs in clinical trials – an update (2010), Hot topic edition with contributions by H. Zhao, R.J. Fram, C.S. Young, D. Nowotnik and F. Kratz,Curr. Bioactive Compounds 7,(ed. F. Kratz).
4. INNO-206 (DOXO-EMCH), an albumin-binding prodrug of doxorubicin for phase II studies against pancreatic, gastric cancer and sarcoma, in Anticancer macromolecular prodrugs in clinical trials – an update (2010), Hot topic edition,Curr. Bioactive Compounds 7(ed. F. Kratz), 33-38.
5. F. Kratz: Drug Delivery in Oncology − Challenges and Perspectives inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
6. K. Mross, F. Kratz: Limits of Conventional Chemotherapy inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
7. K. Abu Ajaj, F. Kratz: Clinical Experience with Drug Polymer Conjugates, inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
8. K. Hochdörffer, G. Gi Stefano, H. Maeda, F. Kratz: Liver Tumor Targeting, inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
9. G. J. Molderings, M. Raithel, F. Kratz, M. Azemar, B. Haenisch, S. Harzer, J. Homann (2011): Omalizumab treatment of systemic mast cell disease: experiences from four cases.Internal Medicine,50, 611-5.
10. M. Calderón, P Welker, K. Licha, I. Fichtner, R. Graeser, R. Haag, F. Kratz (2011): Development of efficient acid-cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell,J. Controlled Release, 151, 295-301.
11. B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, C. Tsurumi, A.Warnecke, C. Unger, T. Saleem, F. Kratz (2011): A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases,Prostate Cancer and Prostate Disease, 14,14-21.
12. M. Shama, C. Ryppa, F. Kratz, D. Raucher (2010): Thermally targeted delivery of an acid-sensitive hydrazone derivative of paclitaxel by elastin-like polypeptide,Investigational New Drugs, [Epub ahead of press].
13. B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, K. Abu Ajaj, C. Unger, A. Warnecke, T. Saleem, N. El-Melegy, H. Madkor, F. Kratz (2010): Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: anin vitroandin vivoevaluation study,Eur. J. Cancer, 46, 3434-44.
14. I. Müller, F. Kratz, M. Jung, A. Warnceke (2010): Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation,Tetrahedron Letters,51, 4371-4374.
15. B. Elsadek, R. Graeser, A. Warnecke, C. Unger, T Saleem,. Nagla El-Melegy, H. Madkor, F. Kratz (2010): Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA),ACS Med. Chem.Lett. 1, 234-238.
16. D. Polyak, C. Ryppa, A. Eldar-Boock, K. Licha, F. Kratz, P. Ofek, R. Satchi-Fainaro (2010): PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for tumor integrin targeting,Polymers for Advanced Technologies, in press.
17. F. Kratz (2010): Albumin, a versatile drug carrier in oncology,Int. J. Clin. Pharm. Ther.48, 453-455.
18. R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, C. Unger, F. Kratz (2010): INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model,Investigational New Drugs,28, 14-19.
19. M. Calderón, P. Welker, K. Licha, R. Graeser R, F. Kratz, R. Haag (2010): Development of efficient macromolecular prodrugs derived from dendritic polyglycerol,J. Controlled Release 20;148(1):e24-5.

Profile Details

Last Updated: August, 2012.

Reference this profile directly: NULL